上海元戊医学技术有限公司

MANAGEMENT TEAM

Ouyang Ping

Chairman

Senior biomedical entrepreneur and entrepreneur.

Leader in the industrialization of innovative drug research and development in stem cell and gene editing technology.

Member of China Democratic National Construction Association, full-time postgraduate degree.

With more than 20 years of professional experience and more than 10 years of front-line work experience in the biomedical industry, he has worked or served as a senior executive, partner and strategic consultant in a number of high-tech R&D pharmaceutical enterprises. In 2021, he founded Shanghai Yuanwu Medical Technology Co., LTD., focusing on the development and application of iPSC (induced pluripotent stem cell) technology.

Have comprehensive work experience in strategic coordination, risk management and control, business development, brand marketing and other aspects.

He will combine promoting industrial development with fulfilling social responsibilities, promote high-quality development of the biomedical industry with technological empowerment and industrial upgrading, and create new economic and social values;

As a partner, he once led the team to build a domestic high-end medical brand into the number one domestic market share and achieve domestic substitution.

Senior biomedical entrepreneur and entrepreneur.

Leader in the industrialization of innovative drug research and development in stem cell and gene editing technology.

Member of China Democratic National Construction Association, full-time postgraduate degree.

With more than 20 years of professional experience and more than 10 years of front-line work experience in the biomedical industry, he has worked or served as a senior executive, partner and strategic consultant in a number of high-tech R&D pharmaceutical enterprises. In 2021, he founded Shanghai Yuanwu Medical Technology Co., LTD., focusing on the development and application of iPSC (induced pluripotent stem cell) technology.

Have comprehensive work experience in strategic coordination, risk management and control, business development, brand marketing and other aspects.

He will combine promoting industrial development with fulfilling social responsibilities, promote high-quality development of the biomedical industry with technological empowerment and industrial upgrading, and create new economic and social values;

As a partner, he once led the team to build a domestic high-end medical brand into the number one domestic market share and achieve domestic substitution.
Jin Jun

General Manager

Doctor of Science and Technology, National Center for Nanoscience, Chinese Academy of Sciences (studied under Academician Chen Chunying);

Industry supervisor for postgraduate degree in biology and medicine at Shanghai University of Science and Technology (stem cell medicine direction);

He has successively conducted research on integrated nanomedicine diagnosis and treatment targeting the tumor microenvironment (TME), research on universal drugs for iPSC-induced pluripotent stem cells, etc., and has many years of experience in biomedical industry research and planning.

He is currently the general manager and chief technology officer of Yuanwu Medical, and led the team to obtain 5 core patent authorizations, including iPSC reprogramming, differentiation, and engineering. He has published a total of 9 papers in multiple academic journals: 2 of them are SCI research papers (ACS Applied Materials & Interface, J Mater Sci Mater Med), 1 joint research paper (Nano Research), and 2 are reviews.

Doctor of Science and Technology, National Center for Nanoscience, Chinese Academy of Sciences (studied under Academician Chen Chunying);

Industry supervisor for postgraduate degree in biology and medicine at Shanghai University of Science and Technology (stem cell medicine direction);

He has successively conducted research on integrated nanomedicine diagnosis and treatment targeting the tumor microenvironment (TME), research on universal drugs for iPSC-induced pluripotent stem cells, etc., and has many years of experience in biomedical industry research and planning.

He is currently the general manager and chief technology officer of Yuanwu Medical, and led the team to obtain 5 core patent authorizations, including iPSC reprogramming, differentiation, and engineering. He has published a total of 9 papers in multiple academic journals: 2 of them are SCI research papers (ACS Applied Materials & Interface, J Mater Sci Mater Med), 1 joint research paper (Nano Research), and 2 are reviews.

CORE R&D TEAM

Wang Xianliu

Head of iMSC Differentiation Platform

Ph.D. in Biomaterials Science, Donghua University.

PhD in Biomedical Joint training at the University of Wisconsin-Madison.

Focus on the field of stem cell behavior regulation, master stem cell identification, directional differentiation, analysis and detection, material-cell interaction and other related research techniques.

He has 9 years of experience in stem cell research projects, has the ability of overall management, has hosted, managed, participated in national projects and achieved research results for many times.

Ph.D. in Biomaterials Science, Donghua University.

PhD in Biomedical Joint training at the University of Wisconsin-Madison.

Focus on the field of stem cell behavior regulation, master stem cell identification, directional differentiation, analysis and detection, material-cell interaction and other related research techniques.

He has 9 years of experience in stem cell research projects, has the ability of overall management, has hosted, managed, participated in national projects and achieved research results for many times.
Xie Tianfa

Head of iNC differentiation Platform

Ph.D. in Engineering from the University of Massachusetts at Amsterdam.

Master of Biochemistry and Molecular Biology, Hefei University of Technology.

Focus on building early mesencephalic and hindbrain spatial development models using pluripotent stem cells and simulating early embryonic development in vitro.

Proficient in in vitro culture and directional differentiation of pluripotent stem cells, and successfully reduce stem cell self-differentiation by optimizing stem cell culture medium.

Ph.D. in Engineering from the University of Massachusetts at Amsterdam.

Master of Biochemistry and Molecular Biology, Hefei University of Technology.

Focus on building early mesencephalic and hindbrain spatial development models using pluripotent stem cells and simulating early embryonic development in vitro.

Proficient in in vitro culture and directional differentiation of pluripotent stem cells, and successfully reduce stem cell self-differentiation by optimizing stem cell culture medium.
Wei Gaobo

Head of Cell Function Analysis Technology Platform

Postdoctoral fellow, Guangzhou Bioisland Laboratory.

PhD in Regenerative medicine, Institute of Zoology, Chinese Academy of Sciences.

He is mainly engaged in the study of epigenetic changes on the regulation mechanism of early embryonic development and chromatin three-dimensional conception in model animals.

Proficient in various labeling technologies and protein profile identification, and able to construct and screen specific transgenic strains with CRISPR/Cas9 technology /Tol2 transposon technology.

Postdoctoral fellow, Guangzhou Bioisland Laboratory.

PhD in Regenerative medicine, Institute of Zoology, Chinese Academy of Sciences.

He is mainly engaged in the study of epigenetic changes on the regulation mechanism of early embryonic development and chromatin three-dimensional conception in model animals.

Proficient in various labeling technologies and protein profile identification, and able to construct and screen specific transgenic strains with CRISPR/Cas9 technology /Tol2 transposon technology.

SCIENTIFIC AND TECHNOLOGICAL COMMISSION

He Zhiying

Chief technologist

Professor and doctoral supervisor, Institute of Translational Medicine, Tongji University;

Principal of National Stem Cell Clinical Research Center;

National stem cell research project leader;

National top scientist for clinical transformation of cellular drugs;

The whole process of R&D-GLP-GCP was designed.

Distinguished Researcher, Executive Director, Project leader, Institute of Regenerative Medicine, East Hospital Affiliated to Tongji University, Director of Shanghai Stem Cell Translational Medicine Engineering Technology Research Center, Director of the Department of Biotechnology, East Clinical School of Tongji University.

Based on the domestic research foundation and team cooperation, with stem cells and liver regeneration as the research direction, the basic and applied research of liver cell transplantation is carried out, and the cell therapy of liver diseases is committed. He has presided over the stem cell and translational research project of the National Key Research and Development Program (Chief scientist), more than 30 projects including the National Natural Science Foundation (6 projects), the National Key Research and Development Program (PI), provincial major projects, and the key projects of the Nature Foundation, and has 5 stem cell invention patents.

On October 26, 2023, the new drug clinical trial application of "Human umbilical cord mesenchymal stem cell Injection" independently developed by Professor He Zhiying and his team was accepted by CDE (CXSL2300728). The project has been filed through the national Stem cell clinical research project in the early stage, and carried out exploratory research, and signed the "Technology transfer (cooperation) contract" with Tasly Pharmaceutical Group in August 2022 (the transfer amount of 60 million plus the income after the drug market).

Academic Achievements: Research results have been published in Nature, Cell Stem Cell, Gastroenterology, Hepatology, Cell Research, NPJ Regenerative Medicine, Biomaterials, American Journal of Pathology, Cell Death & Disease and other international journals.

Professor and doctoral supervisor, Institute of Translational Medicine, Tongji University;

Principal of National Stem Cell Clinical Research Center;

National stem cell research project leader;

National top scientist for clinical transformation of cellular drugs;

The whole process of R&D-GLP-GCP was designed.

Distinguished Researcher, Executive Director, Project leader, Institute of Regenerative Medicine, East Hospital Affiliated to Tongji University, Director of Shanghai Stem Cell Translational Medicine Engineering Technology Research Center, Director of the Department of Biotechnology, East Clinical School of Tongji University.

Based on the domestic research foundation and team cooperation, with stem cells and liver regeneration as the research direction, the basic and applied research of liver cell transplantation is carried out, and the cell therapy of liver diseases is committed. He has presided over the stem cell and translational research project of the National Key Research and Development Program (Chief scientist), more than 30 projects including the National Natural Science Foundation (6 projects), the National Key Research and Development Program (PI), provincial major projects, and the key projects of the Nature Foundation, and has 5 stem cell invention patents.

On October 26, 2023, the new drug clinical trial application of "Human umbilical cord mesenchymal stem cell Injection" independently developed by Professor He Zhiying and his team was accepted by CDE (CXSL2300728). The project has been filed through the national Stem cell clinical research project in the early stage, and carried out exploratory research, and signed the "Technology transfer (cooperation) contract" with Tasly Pharmaceutical Group in August 2022 (the transfer amount of 60 million plus the income after the drug market).

Academic Achievements: Research results have been published in Nature, Cell Stem Cell, Gastroenterology, Hepatology, Cell Research, NPJ Regenerative Medicine, Biomaterials, American Journal of Pathology, Cell Death & Disease and other international journals.
Wang Hongbing

Senior technologist on stem cell drug design

Vice President, College of Life Science and Technology, Tongji University;

Professor, doctoral supervisor;

Visiting Scholar, Faculty of Medicine, University of Hong Kong;

Scientist in the field of aging.

Research direction:

1. Research on molecular biology of aging based on small molecule probes

2. Study on the pathogenesis of neurodegenerative diseases

3. Research on the discovery and mechanism of natural active drugs for delaying aging and treating age-related diseases

He has presided over or participated in a number of national and provincial research funds. Selected in 2011 Tongji University Young Talents Program. He is a member of the Natural Medicine Chemistry Committee of Shanghai Pharmaceutical Society, a national science and technology award review expert, a science and technology evaluation and review system expert of the Ministry of Education, a project review expert of the Shanghai Science and Technology Commission, a dissertation review expert of the Ministry of Education, and a reviewer of several SCI papers.

Academic Achievements: Relevant research results have been published in the international top journals Chemical Reviews, Circulation, Free Radical Biology and Medicine, Endocrinology and the Journal of Natural Products and other important journals in the field. So far, he has published more than 50 research papers, more than 40 have been included in SCI, and applied for 1 international patent (authorized) and 5 Chinese patents (authorized 3).

Vice President, College of Life Science and Technology, Tongji University;

Professor, doctoral supervisor;

Visiting Scholar, Faculty of Medicine, University of Hong Kong;

Scientist in the field of aging.

Research direction:

1. Research on molecular biology of aging based on small molecule probes

2. Study on the pathogenesis of neurodegenerative diseases

3. Research on the discovery and mechanism of natural active drugs for delaying aging and treating age-related diseases

He has presided over or participated in a number of national and provincial research funds. Selected in 2011 Tongji University Young Talents Program. He is a member of the Natural Medicine Chemistry Committee of Shanghai Pharmaceutical Society, a national science and technology award review expert, a science and technology evaluation and review system expert of the Ministry of Education, a project review expert of the Shanghai Science and Technology Commission, a dissertation review expert of the Ministry of Education, and a reviewer of several SCI papers.

Academic Achievements: Relevant research results have been published in the international top journals Chemical Reviews, Circulation, Free Radical Biology and Medicine, Endocrinology and the Journal of Natural Products and other important journals in the field. So far, he has published more than 50 research papers, more than 40 have been included in SCI, and applied for 1 international patent (authorized) and 5 Chinese patents (authorized 3).
Yuan Baozhu

Senior technical expert on stem cell drug quality control

Professor, College of Life Science and Technology, Tongji University;

Former Director of Cell Center, China Institute for Food and Drug Control;

Chief Scientist of the National Stem Cell Transformation Resource Bank;

Member of the National Council of Stem Cell Experts;

The first person to develop the quality evaluation system of stem cells in China;

Chairman & Chief Scientist of Shanghai Zhiding Biotechnology Co., LTD.

Mainly engaged in all kinds of therapeutic cell products quality attribute research, quality standards research and related evaluation technology research, cellular drug technology research and pharmaceutical research. National stem cell quality evaluation system and numerous stem cell quality standards have been established.

As a member of the National Stem Cell Expert Committee, he was responsible for drafting and formulating the Guiding Principles for Quality Control and Preclinical Research of Stem Cell Preparations (Trial) (2015), the first in China to guide clinical transformation research of stem cells; As the chief scientist of the 2016 National "Stem Cell and Translational Research" key project "Establishment of Standardized evaluation system of Stem cells for Clinical Research" to support the research and development of stem cell products in China. Since August 2022, Shanghai Zhuding Biotechnology Co., Ltd. has been established to engage in "quality services" related to cellular drugs and regenerative medicine products.

Professor, College of Life Science and Technology, Tongji University;

Former Director of Cell Center, China Institute for Food and Drug Control;

Chief Scientist of the National Stem Cell Transformation Resource Bank;

Member of the National Council of Stem Cell Experts;

The first person to develop the quality evaluation system of stem cells in China;

Chairman & Chief Scientist of Shanghai Zhiding Biotechnology Co., LTD.

Mainly engaged in all kinds of therapeutic cell products quality attribute research, quality standards research and related evaluation technology research, cellular drug technology research and pharmaceutical research. National stem cell quality evaluation system and numerous stem cell quality standards have been established.

As a member of the National Stem Cell Expert Committee, he was responsible for drafting and formulating the Guiding Principles for Quality Control and Preclinical Research of Stem Cell Preparations (Trial) (2015), the first in China to guide clinical transformation research of stem cells; As the chief scientist of the 2016 National "Stem Cell and Translational Research" key project "Establishment of Standardized evaluation system of Stem cells for Clinical Research" to support the research and development of stem cell products in China. Since August 2022, Shanghai Zhuding Biotechnology Co., Ltd. has been established to engage in "quality services" related to cellular drugs and regenerative medicine products.
Xiang Yangfei

iNSC differentiation platform senior technical expert

Professor, Doctoral Supervisor, Shanghai University of Science and Technology;

Stem Cell and Neurobiology Research Group PI;

National Talent Program (youth);

Postdoctoral fellow, Associate Research Fellow, Yale University.

Winner of Shanghai Talent Program, member of Development and Regeneration Branch of Chinese Neuroscience Society. He has been engaged in brain organoid technology research for nearly ten years. The main contents include the development and application of brain-specific organoids and complex brain organoids based on human pluripotent stem cells. Participated in the national key research and development plan, National Natural Science Foundation, Shanghai Science and Technology Commission and other projects as the project leader.

Academic achievements: The related work has been emphasized in the review articles of Nature, Cell, Cell Stem Cell and other journals, included in the topic of Nature and Cell organoids, and listed as the focus research direction (" Methods to Watch ") by the editorial department of Nature Methods. In 2020 and 2021, the laboratory was twice paid attention by Cell Stem Cell, a well-known journal in the field of stem cells.

Professor, Doctoral Supervisor, Shanghai University of Science and Technology;

Stem Cell and Neurobiology Research Group PI;

National Talent Program (youth);

Postdoctoral fellow, Associate Research Fellow, Yale University.

Winner of Shanghai Talent Program, member of Development and Regeneration Branch of Chinese Neuroscience Society. He has been engaged in brain organoid technology research for nearly ten years. The main contents include the development and application of brain-specific organoids and complex brain organoids based on human pluripotent stem cells. Participated in the national key research and development plan, National Natural Science Foundation, Shanghai Science and Technology Commission and other projects as the project leader.

Academic achievements: The related work has been emphasized in the review articles of Nature, Cell, Cell Stem Cell and other journals, included in the topic of Nature and Cell organoids, and listed as the focus research direction (" Methods to Watch ") by the editorial department of Nature Methods. In 2020 and 2021, the laboratory was twice paid attention by Cell Stem Cell, a well-known journal in the field of stem cells.
Lin Zhaobo

iMSC differentiation platform senior technical expert

Professor, Doctoral Supervisor, Shanghai University of Science and Technology;

Cell Plasticity Research Group PI;

Postdoctoral Fellow, University of California, Berkeley;

A stem cell scientist.

His research direction is stem cell biology, mainly using mice as model organisms to study how non-coding RNA microRNA regulates the potential of pluripotent stem cells, as well as the role of transposon in pluripotent stem cells, and the application of gene editors in stem cells and organoids.

1. Function of stem cells in early embryonic development in mice and humans.

2. Use organoids as models to study the development of mouse and human embryos and the pregnancy diseases caused by their defects.

Application of gene editors in stem cells and organoids.

Academic achievements: Relevant research results have been published in international journals such as Nature Communications, Cell Reports, and Molecular Therapy.

Professor, Doctoral Supervisor, Shanghai University of Science and Technology;

Cell Plasticity Research Group PI;

Postdoctoral Fellow, University of California, Berkeley;

A stem cell scientist.

His research direction is stem cell biology, mainly using mice as model organisms to study how non-coding RNA microRNA regulates the potential of pluripotent stem cells, as well as the role of transposon in pluripotent stem cells, and the application of gene editors in stem cells and organoids.

1. Function of stem cells in early embryonic development in mice and humans.

2. Use organoids as models to study the development of mouse and human embryos and the pregnancy diseases caused by their defects.

Application of gene editors in stem cells and organoids.

Academic achievements: Relevant research results have been published in international journals such as Nature Communications, Cell Reports, and Molecular Therapy.